

(12) EUROPEAN PATENT APPLICATION

(21) Application number : 91810580.0

(51) Int. Cl.<sup>5</sup> : A61K 31/185, A61K 31/19, A61K 31/40, A61K 31/195

(22) Date of filing : 18.07.91

(30) Priority : 19.07.90 JP 192575/90  
23.08.90 JP 223807/90

(43) Date of publication of application :  
22.01.92 Bulletin 92/04

(84) Designated Contracting States :  
AT BE CH DE DK ES FR GB GR IT LI LU NL SE


(71) Applicant : NIPPON ZOKI PHARMACEUTICAL  
CO. LTD.  
10, Hiranomachi Nichome, Higashi-ku  
Osaka (JP)

(72) Inventor : Higashiura, Kunihiro, Inst. of  
Bio-Active Science  
Nippon Zoki Pharma. Co., Ltd, 442-1, Kinashi  
Yashiro-cho, Katoh-gun, Hyogo (JP)  
Inventor : Ienaga, Kazuharu, Inst. of Bio-Active  
Science  
Nippon Zoki Pharma. Co., Ltd, 442-1, Kinashi  
Yashiro-cho, Katoh-gun, Hyogo (JP)  
Inventor : Hattori, Masao  
2-1, Minamitaikouyama, Kosugi-machi  
Izumi-gun, Toyama (JP)

(74) Representative : Kerr, Andrew  
A.KERR AG, Postfach, Finkelerweg 44  
CH-4144 Arlesheim (CH)

(54) Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases.

(57) The present invention relates to a pharmaceutical composition for use in preventing or treating heart diseases in a mammal, which comprises at least one aminoalkanesulfonic acid derivative of the formula (I) :



wherein X is hydrogen or an amino acid residue ; Y is hydrogen, a phenyl group or an alkyl group, which may have a hydroxy, amino, carboxy, phenyl or hydroxyphenyl group ; or X and Y are joined to form a trimethylene or hydroxytrimethylene group ; and at least one of X and Y is other than hydrogen ; or pharmaceutically acceptable salt thereof.

EP 0 467 856 A2

21044  
#22

The present invention relates to an aminoalkanesulfonic acid derivative and a pharmaceutical composition for use in preventing or treating heart diseases.

Myocardial cells maintain the homeostasis of calcium through the cell membrane. When the functional disorders of the cell membrane are induced or excessive calcium ions ( $\text{Ca}^{2+}$ ) are overloaded in myocardial cells by the drug effects etc., the myocardial cells are obstructed and that causes cardiomyopathy or myocardial necrosis.

When isolated hearts are re-perfused with  $\text{Ca}^{2+}$  containing medium after a short period of  $\text{Ca}^{2+}$ -free perfusion, contraction of myofibrils, loss of electrical activity, rupture of myocardial cells, flux of intracellular enzymes and the like are observed. This phenomenon was termed the "calcium paradox", and it has been suggested that the  $\text{Ca}^{2+}$ -overload played an important part in the occurrence of this phenomenon. Namely, it was proposed that the  $\text{Ca}^{2+}$ -overload causes cardiomyopathy at blood re-circulation after ischemia accompanied with ischemic heart diseases and heart operations. Finally the calcium paradox causes irreversible changes of myocardial cells. It was reported that this dysfunction resulting from the calcium paradox was reduced by drugs such as calcium antagonist.

The inventors have found that the aminoalkanesulfonic acid derivative of the present invention has an excellent protective effect against cardiomyopathy resulting from the  $\text{Ca}^{2+}$ -overload and improving effect on hypofunction of hearts in the low  $\text{Ca}^{2+}$  concentration.

An object of the present invention is to provide a pharmacological composition for use in treating or preventing heart diseases, which comprises as an active ingredient an effective amount of at least one aminoalkanesulfonic acid derivative or pharmaceutically acceptable salt thereof. Another object of the invention is to provide the use of the aminoalkanesulfonic acid derivative and pharmaceutically acceptable salt thereof, for the manufacture of pharmaceutical composition for use in preventing or treating heart diseases in a mammal. Further object of the invention is to provide novel aminoalkanesulfonic acid derivatives or pharmaceutically acceptable salts thereof, which are useful as preventive medicine or remedy for various heart diseases.

The present invention mainly relates to a pharmaceutical composition for use in preventing or treating heart diseases in a mammal, which comprises at least one aminoalkanesulfonic acid derivative of the following formula (I) or pharmaceutically acceptable salt thereof.



In the formula (I), X is hydrogen or an amino acid residue, preferably glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, proline, hydroxyproline, aspartic acid,  $\beta$ -aspartic acid, glutamic acid,  $\gamma$ -glutamic acid, phenylalanine, tyrosine and the like; Y is hydrogen, a phenyl group or an alkyl group, preferably a straight or branched alkyl group having 1 to 5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neo-pentyl or t-pentyl, which may have a hydroxy, amino, carboxy, phenyl or hydroxyphenyl group; or X and Y are joined to form a trimethylene or hydroxytrimethylene group; and at least one of X and Y is other than hydrogen.

Preferred compounds of the present invention are indicated as follows:

No.	Name
1	Glycyltaurine
2	Alanyltaurine
3	Valyltaurine
4	Leucyltaurine
5	Isoleucyltaurine
6	Seryltaurine
7	Threonyltaurine
8	Methionyltaurine
9	Prolyltaurine
10	Hydroxypropyltaurine
11	Aspartyltaurine
12	$\beta$ -Aspartyltaurine
13	Glutamyltaurine
14	$\gamma$ -Glutamyltaurine
15	Phenylalanyltaurine

- 16    Tyrosyltaurine
- 17    2-Aminopropanesulfonic acid
- 18    2-Amino-3-methylbutanesulfonic acid
- 19    2-Amino-4-methylpentanesulfonic acid
- 5    20    2-Amino-3-methylpentanesulfonic acid
- 21    2-Amino-3-hydroxypropanesulfonic acid
- 22    2-Amino-3-hydroxybutanesulfonic acid
- 23    2-Pyrrolidinylmethanesulfonic acid
- 24    2-(4-Hydroxypyrrolidinyl)methanesulfonic acid
- 10    25    3-Amino-4-sulfobutyric acid
- 26    4-Amino-5-sulfopentanoic acid
- 27    2,6-Diaminohexanesulfonic acid
- 28    2,5-Diaminopentanesulfonic acid
- 29    2-Amino-3-phenylpropanesulfonic acid
- 15    30    2-Amino-3-(4-hydroxyphenyl)propanesulfonic acid
- 31    2-Amino-2-phenylethanesulfonic acid

The aminoalkanesulfonic acid derivatives of the present invention include pharmaceutically acceptable salts of the compounds having formula (I) above, for example, salts as acid addition with an acid such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid, perchloric acid, thiocyanic acid, boric acid, formic acid, acetic acid, haloacetic acid, propionic acid, glycolic acid, citric acid, tartaric acid, succinic acid, glyconic acid, lactic acid, malonic acid, fumaric acid, anthranilic acid, benzoic acid, cinnamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid or sulfanilic acid, salts with alkali metal such as sodium or potassium, salts with alkaline-earth metal such as calcium, magnesium or barium, or salts with other metals such as aluminum.

The aminoalkanesulfonic acid derivatives of this invention may also include their metal complexes, for example, complexes with zinc, nickel, cobalt, copper, iron etc.

These salts and metal complexes can be produced from free aminoalkanesulfonic acid derivatives in the usual way or can be interchanged with each other.

When optical isomers exist in the compounds of the invention, the present invention includes any types of isomers.

Several aminoalkanesulfonic acid derivatives of the present invention and a process for manufacturing them are disclosed in Chem. Pharm. Bull. 36(1), 70-77 (1988), Chem. Pharm. Bull. 36(8), 2796-2801 (1988), J. Chem. Soc. Perkin Trans. I, 1479-1481 (1989) and the like.

The aminoalkanesulfonic acid derivatives of the present invention include novel compounds represented by the following formula (I').

35



40

In the formula (I'), X is hydrogen or a methionyl group; Y is hydrogen, an isobutyl group, sec-butyl group, hydroxyethyl group, carboxyalkyl group such as carboxymethyl, carboxyethyl or carboxypropyl, aminoalkyl group such as aminomethyl, aminoethyl, aminopropyl or aminobutyl, or hydroxyphenylalkyl group such as hydroxyphenylmethyl or hydroxyphenylethyl; or X and Y are joined to form a trimethylene or hydroxytrimethylene group; and at least one of X and Y is other than hydrogen.

The said novel aminoalkanesulfonic acid derivatives may be produced according to the process disclosed in the above mentioned papers, and the physicochemical data of the embodiments of them are shown as follows. The specific rotation was measured using sodium lamp ( $\lambda=5893\text{\AA}$ ).

50    Methionyltaurine (compound 8)

m.p.: 291 - 293 °C (decomposition)

$[\alpha]_{20}^{20}$ : +34.3° (c=1.0, H<sub>2</sub>O)

NMR(0.1NDCI, t-BuOD,  $\delta=1.23\text{ppm}$ ):  $\delta=2.10(3\text{H},\text{s})$ , 2.09-2.24(2H,m), 2.60(1H,ddd,J=7Hz,7Hz,14Hz), 2.63(1H,ddd,J=7Hz,7Hz,14Hz), 3.11(2H,t,J=6.5Hz), 3.62(1H,ddd,J=6.5Hz,6.5Hz,14Hz), 3.66 (1H,ddd, J=6.5Hz, 6.5Hz,14Hz), 4.10(1H,t,J=7Hz)

55

Elementary Analysis: C<sub>7</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub>

		C %	H %	N %
	Calculated	32.80	6.29	10.93
5	Found	32.72	6.48	10.64

## D-Methionyltaurine

m.p.: 291 - 293 °C (decomposition)

10  $[\alpha]^{20}_D$ : -34.2° (c=1.0, H<sub>2</sub>O)Elementary Analysis: C<sub>7</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub>

		C %	H %	N %
	Calculated	32.80	6.29	10.93
15	Found	32.94	6.43	11.03

## 20 2-Amino-4-methylpentanesulfonic acid (compound 19)

m.p.: &gt; 300 °C

 $[\alpha]^{20}_D$ : +15.5° (c=1.0, H<sub>2</sub>O)NMR(0.2N NaOD, t-BuOD,  $\delta$ =1.23ppm):  $\delta$ =0.89(3H,d,J=7Hz), 0.90(3H,d,J=7Hz), 1.30(2H,dd,J=7Hz, 7Hz), 1.67(1H,dqq,J=7Hz,7Hz,7Hz), 2.78(1H,dd,J=9Hz,14Hz), 3.01(1H,dd,J=3Hz,14Hz), 3.29 (1H, ddt, J=3Hz,9Hz,7Hz)

## 25 2-Amino-3-methylpentanesulfonic acid (compound 20)

m.p.: 292 - 293 °C

 $[\alpha]^{24}_D$ : +24.8° (c=1.0, H<sub>2</sub>O)Elementary Analysis: C<sub>6</sub>H<sub>15</sub>NO<sub>3</sub>S

		C %	H %	N %
	Calculated	39.76	8.34	7.73
30	Found	39.81	8.52	7.62

35 NMR(0.2NaOD, t-BuOD,  $\delta$ =1.23ppm): $\delta$ =0.86(3H,d,J=7.5Hz), 0.89(3H,t,J=7.5Hz), 1.12-1.24(1H,m), 1.31-1.42(1H,m), 1.46-1.57(1H,m), 2.75(1H,dd,J=10Hz,15Hz), 3.03(1H,dd,J=2Hz,15Hz), 3.15-3.20(1H,m)

2-Amino-3-hydroxybutanesulfonic acid (compound 22)

40 m.p.: 220 - 222 °C

 $[\alpha]^{24}_D$ : +15.5° (c=1.0, H<sub>2</sub>O)Elementary Analysis: C<sub>4</sub>H<sub>11</sub>NO<sub>4</sub>S

		C %	H %	N %
	Calculated	28.40	6.55	8.28
45	Found	28.10	6.35	7.95

50 NMR(0.2NaOD, t-BuOD,  $\delta$ =1.23ppm): $\delta$ =1.17(3H,d,J=6.5Hz), 2.83(1H,dd,J=9Hz,14Hz), 3.10(1H,dd,J=2.5Hz,14Hz), 3.11-3.17(1H,m), 3.77-3.84(1H,m)

2-Pyrrolidinylmethanesulfonic acid (compound 23)

55 m.p.: 307 - 308 °C (decomposition)

 $[\alpha]^{24}_D$ : +33.4° (c=1.0, H<sub>2</sub>O)Elementary Analysis: C<sub>5</sub>H<sub>11</sub>NO<sub>3</sub>S

## EP 0 467 856 A2

	C %	H %	N %
Calculated	36.35	6.71	8.48
5 Found	36.43	6.94	8.37

NMR(0.2NaOD, t-BuOD,  $\delta$ =1.23ppm):

10  $\delta$ =1.45(1H,ddd,J=8Hz,8Hz,9.5Hz,13Hz), 1.67-1.83(2H,m), 2.20(1H,ddd,J=5Hz,7Hz,8Hz,13Hz), 2.78(1H,ddd,J=7Hz,8Hz,10Hz), 2.89(1H,ddd,J=6Hz,7Hz,10Hz), 3.01(1H,dd,J=6.5Hz,14Hz), 3.04(1H,dd,J=6.5Hz,14Hz), 3.23-3.40(1H,m)

2-(4-Hydroxypyrrolidinyl)methanesulfonic acid (compound 24)

m.p.: > 330 °C

[ $\alpha$ ]<sup>20</sup>: +28.1° (c=1.0, H<sub>2</sub>O)

15 Elementary Analysis: C<sub>5</sub>H<sub>11</sub>NO<sub>4</sub>S

	C %	H %	N %
20 Calculated	33.14	6.12	7.73
Found	32.92	6.42	7.41

NMR(0.2NaOD, t-BuOD,  $\delta$ =1.23ppm):

25  $\delta$ =1.72(1H,ddd,J=6Hz,10Hz,14Hz), 2.03(1H,ddt,J<sub>d</sub>=6.5Hz,14Hz,J<sub>t</sub>=1.5Hz), 2.75(1H,ddd,J=1Hz,3Hz,11.5Hz), 3.01(1H,dd,J=7Hz,14Hz), 3.08(1H,dd,J=6.5Hz,14Hz), 3.15(1H,dd,J=5.5Hz,11.5Hz), 3.60-3.68(1H,m), 4.40-4.45(1H,m)

3-Amino-4-sulfobutyric acid (compound 25)

m.p.: 266 - 267 °C (decomposition)

30 [ $\alpha$ ]<sup>23</sup>: -4.7° (c=1.0, H<sub>2</sub>O)

NMR(0.2NaOD, t-BuOD,  $\delta$ =1.23ppm):

$\delta$ =2.28(1H,dd,J=8.5Hz,15Hz), 2.41(1H,dd,J=5.5Hz,15Hz), 2.87(1H,dd,J=8.5Hz,14Hz), 3.03(1H,dd,J=3Hz,14Hz), 3.57(1H,dddd,J=3Hz,3.5Hz,5.5Hz,8.5Hz)

4-Amino-5-sulfopentanoic acid (compound 26)

35 m.p.: 257 - 258 °C (decomposition)

[ $\alpha$ ]<sup>24</sup>: +16.9° (c=1.0, H<sub>2</sub>O)

Elementary Analysis: C<sub>5</sub>H<sub>11</sub>NO<sub>5</sub>S

	C %	H %	N %
40 Calculated	30.45	5.62	7.10
Found	30.30	5.89	6.95

45 NMR(0.2NaOD, t-BuOD,  $\delta$ =1.23ppm):  $\delta$ =1.97(2H,dt,J<sub>d</sub>=7.5Hz,J<sub>t</sub>=7Hz), 2.28-2.41(2H,m), 3.13(1H,dd,J=9.5Hz,15Hz), 3.25(1H,dd,J=3Hz,15Hz), 3.61-3.69(1H,m)

2,6-Diaminohexanesulfonic acid (compound 27)

m.p.: 192 - 194 °C

50 [ $\alpha$ ]<sup>23</sup>: +10.4° (c=1.0, H<sub>2</sub>O)

NMR(0.2NaOD, t-BuOD,  $\delta$ =1.23ppm):  $\delta$ =1.29-1.62(6H,m), 2.74-2.85(2H,m), 2.82(1H,dd,J=9Hz,14Hz),

3.03(1H,dd,J=3Hz,15Hz), 3.19-3.26(1H,m)

2,5-Diaminopentanesulfonic acid (compound 28)

m.p.: 277 - 278 °C

55 [ $\alpha$ ]<sup>24</sup>: +12.7° (c=1.0, H<sub>2</sub>O)

Elementary Analysis: C<sub>5</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>S·HCl

	C %	H %	N %
Calculated	27.46	6.91	12.81
5 Found	27.49	6.97	12.86

NMR(0.2NNaOD, t-BuOD,  $\delta$ =1.23ppm):

10  $\delta$ =1.50(1H,dddd,J=6Hz,7Hz,9Hz,14Hz), 1.61(1H,dddd,J=5Hz,6Hz,9Hz,14Hz), 1.64-1.78(2H,m), 2.87(1H,dd,J=9Hz,14Hz), 2.93(1H,ddd,J=7Hz,7Hz,13Hz), 2.96(1H,ddd,J=7Hz,7Hz,13Hz), 3.04(1H, dd, J=3.5Hz, 14Hz), 3.25(1H,dddd,J=3.5Hz,5Hz,7Hz,9Hz)

2-Amino-3-(4-hydroxyphenyl)propanesulfonic acid (compound 30)

m.p.: > 330 °C

$[\alpha]_D^{24}$ : -4.7° (c=0.5, H<sub>2</sub>O)

15 Elementary Analysis: C<sub>9</sub>H<sub>13</sub>NO<sub>4</sub>S

	C %	H %	N %
20 Calculated	46.75	5.76	6.06
Found	46.68	5.86	6.16

NMR(0.2NNaOD, t-BuOD,  $\delta$ =1.23ppm):

25  $\delta$ =2.50(1H,dd,J=8Hz,14Hz), 2.50(1H,dd,J=8Hz,14Hz), 2.69(1H,dd,5.5Hz,14Hz), 2.83(1H, dd, 9Hz, 14Hz), 3.06(1H,dd,J=3Hz,14Hz), 3.38-3.45(1H,m), 5.56-6.61(2H,m), 6.99-7.03(2H,m)

The following examples, which are illustrative only and not intended to limit the scope of the invention, describe the preparation of the novel compounds of the present invention.

#### 30 Example 1

7.48 g of t-butoxycarbonylmethionine and 5.91 g of N-hydroxy-5-norbornene-2,3-dicarboxyimide were dissolved in the mixture of 75 ml of tetrahydrofuran and 75 ml of dioxane. 6.81 g of dicyclohexylcarbodiimide was added thereto in an ice-cold water. The reaction mixture was stirred for 2 hours in an ice-cold water and 20 hours at room temperature. After the precipitated dicyclohexyl urea was filtered off, the solvent was evaporated under reduced pressure. The residue was dissolved in 75 ml dioxane. 50 ml of an aqueous solution of taurine sodium salt, which was prepared by 3.75 g of taurine and 2.52 g of sodium hydrogencarbonate, was added at room temperature and was stirred for 20 hours. After the insoluble material was filtered off, the solvent was evaporated under reduced pressure. The residue was dissolved in 100 ml of water, and washed with ethyl acetate. The aqueous layer was passed through cation-exchange resins to desalt and remove the protecting group. The eluent was evaporated under the reduced pressure, and the residue was treated with 4N hydrogen chloride/dioxane. After evaporation of the solvent, the precipitated white crystals were obtained by filtration with ethanol, and recrystallized with the mixture of water and ethanol to give 5.34 of methionyltaurine (compound 8)

In the same manner, D-methionyltaurine was obtained.

#### 45 Example 2.

(1) Under argon atmosphere, 11.8 g of N-benzyloxycarbonyl-L-prolinol and 13.9 g of triphenylphosphine were dissolved in 150 ml of tetrahydrofuran. In an ice-cold water, 8.4 ml of diethyl azodicarbonate, and then 3.8 ml of thioacetic acid were added. After stirring for 2 hours in an ice-cold water and for 20 hours at room temperature, the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography to give 11.96 g of 2-(1-benzyloxycarbonylpyrrolidinyl)methyl ethanethioate as an oily substance.

55 (2) A performic acid solution was prepared by stirring 24 ml of 30% aqueous solution of hydrogen peroxide and 240 ml of 98% formic acid for one hour at room temperature. This solution was cooled, and then a formic acid solution of the said 2-(1-benzyloxycarbonylpyrrolidinyl)methyl ethanethioate was added dropwise during 30 minutes. After stirring for 2 hours in an ice-cold water and for 20 hours at room temperature, 5 g of 10% Pd/C was added to decompose excess peroxide. Further Pd/C was added, and the solution

was stirred for 10 hours under hydrogen atmosphere. After the catalyst was filtered off, the solvent was evaporated under reduced pressure to give 5.78 g of 2-Pyrrolodinylnmethanesulfonic acid (compound 23) as white crystals.

In the same manner, the compounds 19, 20, 22, 24, 25, 26, 27, 28 and 30 were obtained.

5 The following descriptions serve to illustrative pharmacological studies of the compounds of the present invention.

(1) The heart was removed from 14- to 16-day-old mouse fetus (ICR strain) and was cut in small pieces. The medium containing 0.06% trypsin and 0.01% collagenase was added, and incubated for 10 minutes at 37°C to disperse the cells. Eagle's minimum essential medium (Eagle MEM) supplemented with 10% fetal bovine  
10 serum was added and the cells were collected by centrifugation and dispersed again in a culture medium. Since the attachment time of myocardial cells is different from that of fibroblast-like cells, the dispersed cell solution was incubated for one hour at 37°C under a water-saturated atmosphere of 5% CO<sub>2</sub> in the air and the fibroblast-like cells were removed. The obtained myocardial cells were pre-incubated at a concentration of from 2x 10<sup>5</sup> to 4 x 10<sup>5</sup> cells per one milliliter and then used in the Ca<sup>2+</sup> paradox test.

15 After the culture medium was removed, one milliliter of EGTA medium (Ca<sup>2+</sup>-free) containing a test compound was added and incubated for 10 minutes at 20°C - 22°C. Then the cells were washed with Ca<sup>2+</sup>-free medium containing the test compound and no EGTA, then the medium was rapidly replaced by 1mM Ca<sup>2+</sup> medium, and morphological changes such as blebs, balloon formation etc. of the cells were observed one minute after.

20 The results are shown in Table 1 and Table 2.

25

30

35

40

45

50

55

Table 1

5	Test compound	The percentage of cells showing morphological changes (%)
10	control	$47.4 \pm 3.5$
	compound 1 (10 mM)	$33.2 \pm 0.8$
15	compound 2 (10 mM)	$40.5 \pm 5.3$
	compound 3 (10 mM)	$37.4 \pm 0.7$
	compound 4 (10 mM)	$40.3 \pm 1.9$
20	compound 5 (10 mM)	$40.7 \pm 2.8$
	compound 6 (10 mM)	$43.4 \pm 2.3$
	compound 8 (10 mM)	$27.9 \pm 2.7$
25	compound 9 (10 mM)	$35.6 \pm 4.2$
	compound 10 (10 mM)	$28.2 \pm 2.7$
30	compound 11 (10 mM)	$40.3 \pm 4.9$
	compound 12 (10 mM)	$38.2 \pm 3.0$
	compound 13 (10 mM)	$32.6 \pm 3.0$
35	compound 14 (10 mM)	$36.7 \pm 1.7$
	compound 15 (10 mM)	$34.3 \pm 4.2$

45

50

55



Table 2

5

The percentage of cells showing

Test compound

morphological changes (%)

10

control 51.4 ± 2.4

compound 17 (10 mM) 34.0 ± 2.0

15

compound 18 (10 mM) 42.8 ± 4.2

compound 19 (10 mM) 41.4 ± 4.2

compound 20 (10 mM) 36.2 ± 4.2

20

compound 21 (10 mM) 36.6 ± 2.4

compound 22 (10 mM) 40.2 ± 2.6

25

compound 23 (10 mM) 28.5 ± 1.5

compound 24 (10 mM) 38.8 ± 2.8

compound 25 (10 mM) 32.8 ± 3.8

30

compound 26 (10 mM) 33.6 ± 2.5

compound 28 (10 mM) 33.7 ± 1.5

35

compound 29 (10 mM) 40.9 ± 2.5

compound 30 (10 mM) 46.3 ± 3.5

compound 31 (10 mM) 42.5 ± 2.9

40


(2) The pulse amplitude of myocardial cells was lowered by replacing the culture medium with low  $\text{Ca}^{2+}$  medium. The test compound was added to the low  $\text{Ca}^{2+}$  medium (0.5mM  $\text{Ca}^{2+}$ ) and its effect on the lowered pulse amplitude of myocardial cells was studied. An example of the results is shown in Figure 1.

As clearly shown by the results in Table 1 and Table 2, the aminoalkanesulfonic acid derivatives of the present invention have excellent protective effects on myocardial cells against morphological changes caused by the  $\text{Ca}^{2+}$  paradox. And the results in Figure 1 show that the compounds of this invention significantly reduced the lowering of pulse amplitude of myocardial cells induced in the low  $\text{Ca}^{2+}$  culture medium.

Thus the compounds of the present invention have protective effect against myocardial disorders caused by  $\text{Ca}^{2+}$ -overload and the like, and also normalizing effect on myocardial cells, i.e. reduce the lowering of pulse amplitude of myocardial cells. Therefore, the aminoalkanesulfonic acid derivatives are useful as preventive medicine or remedy for various heart diseases, for example, ischemic heart disease such as myocardial infarction, myocardial disorders under ischemic state during the heart operation, heart failure, angina pectoris and the like.

## Claims


1. A pharmaceutical composition for use in preventing or treating heart diseases in a mammal, which comprises at least one aminoalkanesulfonic acid derivative of the formula (I):



wherein X is hydrogen or an amino acid residue; Y is hydrogen, a phenyl group or an alkyl group, which may have a hydroxy, amino, carboxy, phenyl or hydroxyphenyl; or X and Y are joined to form a trimethylene or hydroxytrimethylene group; and at least one of X and Y is other than hydrogen, or a pharmaceutically acceptable salt or a metal complex thereof.


2. A pharmaceutical composition according to claim 1 wherein X is hydrogen.
3. A pharmaceutical composition according to claim 1 wherein X is an amino acid residue.
4. A pharmaceutical composition according to claim 3 wherein the amino acid is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, proline, hydroxyproline, aspartic acid, beta-aspartic acid, glutamic acid, gamma-glutamic acid, phenylalanine or thyrosine.
5. A pharmaceutical composition according to any of the claims 1,3 or 4 wherein Y is hydrogen.
6. A pharmaceutical composition according to any of the claims 1 to 4 wherein Y is a phenyl group.
7. A pharmaceutical composition according to any of the claims 1 to 4 wherein Y is a straight or branched chain alkyl group having 1 to 5 carbon atoms.
8. A pharmaceutical composition according to claim 7 wherein Y is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neo-pentyl or t-pentyl, optionally substituted by a hydroxy, amino, phenyl or hydroxyphenyl group.
9. A pharmaceutical composition according to claim 1 wherein X and Y are joined to form a trimethylene or hydroxytrimethylene group.
10. A pharmaceutical composition according to claim 1, wherein the compound of formula (I) is: glycyltaurine; alanyltaurine; valyltaurine; leucyltaurine; isoleucyltaurine; seryltaurine; threonyltaurine; methionyltaurine; prolyltaurine; hydroxyprolyltaurine; aspartyltaurine; beta-aspartyltaurine; glutamyltaurine; gamma-glutamyltaurine; phenylalanyltaurine; tyrosyltaurine; 2-aminopropanesulfonic acid; 2-amino-3-methylpentanesulfonic acid; 2-amino-4-methylpentanesulfonic acid; 2-amino-3-methylpentanesulfonic acid; 2-amino-3-hydroxypropanesulfonic acid; 2-amino-3-hydroxybutanesulfonic acid; 2-pyrrolidinylmethanesulfonic acid; 2-(4-hydroxypyrrolidinyl)methanesulfonic acid; 3-amino-4-sulfobutyric acid; 4-amino-5-sulfopentanoic acid; 2,6-diaminohexanesulfonic acid; 2,5-diaminopentanesulfonic acid; 2-amino-3-phenylpropanesulfonic acid; 2-amino-3-(4-hydroxyphenyl)propanesulfonic acid or 2-amino-2-phenylethanesulfonic acid.
11. The use of an aminoalkanesulfonic acid derivative as defined in any one of the preceding claims or a pharmaceutically acceptable salt or metal complex thereof for use in preventing or treating heart diseases in a mammal.
12. A pharmaceutical composition containing a compound of the formula (I) or a pharmaceutically acceptable salt or metal complex thereof as defined in any of claims 1 to 10.
13. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or metal complex thereof as defined in any of claims 1 to 10 for the prevention or treatment of heart diseases in a mammal.

14. An aminoalkanesulfonic acid derivative of the formula (I'):




wherein X is hydrogen, or a methionyl group; Y is hydrogen, an isobutyl group, sec-butyl group, hydroxyethyl group, carboxyalkyl group, aminoalkyl group or hydroxyphenylalkyl group; or X and Y are joined to form a trimethylene or hydroxytrimethylene group; and at least one of X and Y is other than hydrogen, and a pharmaceutically acceptable salt thereof.

15. An aminoalkanesulfonic acid derivative according to claim 14 wherein the carboxyalkyl group is carboxymethyl, carboxyethyl or carboxypropyl.
16. An aminoalkanesulfonic acid derivative according to claim 14 wherein the aminoalkyl group is aminomethyl, aminoethyl or aminopropyl.
17. An aminoalkanesulfonic acid derivative according to claim 14 wherein X is hydrogen.
18. An aminoalkanesulfonic acid derivative according to claim 14 wherein X is a methionyl group.
19. An aminoalkanesulfonic acid derivative according to claim 14 wherein X and Y are joined to form a trimethylene or hydroxytrimethylene group.
20. Methionyltaurine; 2-amino-4-methylpentanesulfonic acid; 2-amino-3-methylpentanesulfonic acid; 2-amino-3-hydroxybutanesulfonic acid; 2-pyrrolidinylmethanesulfonic acid; 2-(4-hydroxypyrrolidinyl) methanesulfonic acid; 3-amino-4-sulfobutyric acid; 4-amino-5-sulfopentanoic acid; 2,6-diaminohexanesulfonic acid; 2,5-diaminopentanesulfonic acid; 2-amino-3-(4-hydroxyphenyl)propanesulfonic acid.
21. A process for the production of aminoalkanesulfonic acid derivatives a pharmaceutically acceptable salt or metal complex thereof as defined in any one of claims 1 to 10, from the corresponding free aminoalkanesulfonic acid or a derivative thereof.
22. A process for preparation of a pharmaceutical composition comprising bringing at least one aminoalkanesulfonic acid derivative of the formula (I):



wherein X is hydrogen or an amino acid residue; Y is hydrogen, a phenyl group or an alkyl group, which may have a hydroxy, amino, carboxy, phenyl or hydroxyphenyl group; or X and Y are joined to form a trimethylene or hydroxytrimethylene group; and at least one of X and Y is other than hydrogen, and pharmaceutically acceptable salts and metal complexes thereof as an active ingredient, into association with at least one pharmaceutically acceptable carrier therefor.

Figure 1





Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number : **0 467 856 A3**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number : **91810580.0**

(22) Date of filing : **18.07.91**

(51) Int. Cl.<sup>5</sup> : **A61K 31/185, A61K 31/19, A61K 31/40, A61K 31/195, C07C 309/14, C07C 309/18, C07C 309/24, C07C 233/60, C07D 207/08, C07D 207/12**

(30) Priority : **19.07.90 JP 192575/90**  
**23.08.90 JP 223807/90**

(43) Date of publication of application :  
**22.01.92 Bulletin 92/04**

(84) Designated Contracting States :  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

(88) Date of deferred publication of search report :  
**14.10.92 Bulletin 92/42**


(71) Applicant : **NIPPON ZOKI PHARMACEUTICAL CO. LTD.**  
**10, Hiranomachi Nichome, Higashi-ku**  
**Osaka (JP)**

(72) Inventor : **Higashiura, Kunihiko, Inst. of Bio-Active Science**  
**Nippon Zoki Pharma. Co., Ltd, 442-1, Kinashi Yashiro-cho, Katoh-gun, Hyogo (JP)**  
Inventor : **Ienaga, Kazuharu, Inst. of Bio-Active Science**  
**Nippon Zoki Pharma. Co., Ltd, 442-1, Kinashi Yashiro-cho, Katoh-gun, Hyogo (JP)**  
Inventor : **Hattori, Masao**  
**2-1, Minamitaikouyama, Kosugi-machi Izumi-gun, Toyama (JP)**

(74) Representative : **Kerr, Andrew**  
**A.KERR AG, Postfach, Finkelerweg 44**  
**CH-4144 Arlesheim (CH)**

(54) **Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases.**

(57) The present invention relates to a pharmaceutical composition for use in preventing or treating heart diseases in a mammal, which comprises at least one aminoalkanesulfonic acid derivative of the formula (I) :



wherein X is hydrogen or an amino acid residue ; Y is hydrogen, a phenyl group or an alkyl group, which may have a hydroxy, amino, carboxy, phenyl or hydroxyphenyl group ; or X and Y are joined to form a trimethylene or hydroxytrimethylene group ; and at least one of X and Y is other than hydrogen ; or pharmaceutically acceptable salt thereof.

EP 0 467 856 A3

Jouve, 18, rue Saint-Denis, 75001 PARIS



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 91 81 0580

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
X	COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, vol. 69C, no. 2, 1981, pages 411-414, Pergamon Press Ltd, GB; L. FEUER et al.: "Effect of litoralon, taurine and other taurine derivatives on the heart muscle cell membrane of the Locusta migratoria (migratorioides R.F.)" * Whole document *	1,3-5, 10-13, 22	A 61 K 31/185 A 61 K 31/19 A 61 K 31/40 A 61 K 31/195 C 07 C 309/14 C 07 C 309/18 C 07 C 309/24 C 07 C 233/60 C 07 D 207/08 C 07 D 207/12
X	PATENT ABSTRACTS OF JAPAN, vol. 12, no. 501 (C-556), 27th December 1988; & JP-A-63 211 261 (NIPPON ZOKI PHARMACEUT. CO., LTD) 02-09-1988 * Whole abstract *	1,3-5, 10,12, 21,22	
X	JP-B-49 004 210 (TAISHO PHARM. CO., LTD) * Derwent abstract *	1,3-5, 10,12, 21	
P,X	PATENT ABSTRACTS OF JAPAN, vol. 14, no. 562 (C-0788), 13th December 1990; & JP-A-2 243 619 (THE GREEN CROSS CORP.) 27-09-1990 * Whole abstract *	1,2,5,7, 8,11-14,17, 22	TECHNICAL FIELDS SEARCHED (Int. Cl. 5)  A 61 K C 07 C C 07 D
Y	FR-M- 3 189 (SOCIETE PHARMACO-BIOLOGIQUE) * Whole document *	1-13,22	
Y	EP-A-0 069 674 (S.A.R.L. BFB ETUDES ET RECHERCHES EXPERIMENTALES) * Whole document *	1-13,22	
-/-			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 03-07-1992	Examiner GAC G.
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.92 (P0401)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 91 81 0580

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)	
Y	EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 110, no. 3, 1985, pages 385-387, Elsevier Science Publishers B.V.; J.B. LOMBARDINI: "Opposite effects of 2-aminoethanesulfonic acid (taurine) and aminomethanesulfonica acid on calcium ion uptake in rat retinal preparations" * Whole document *	1-13,22		
Y	JOURNAL OF MAGNETIC RESONANCE, vol. 89, no. 2, 16th August 1990, pages 391-398, Academic Press, Inc.; A.D. SHERRY et al.: "Formation of carbamates of taurine and other amino acids during neutralization of tissue extracts with potassium carbonate/bicarbonate" * Whole document *	1-13,22		
Y	FR-M- 7 241 (ISTITUTO FARMACOCHEMICO FALORNI S.p.A.) * Whole document *	1-13,22		TECHNICAL FIELDS SEARCHED (Int. Cl.5)
Y	PATENT ABSTRACTS OF JAPAN, vol. 7, no. 139 (C-171), 17th June 1983; & JP-A-58 052 253 (TANABE SEIYAKU K.K.) 28-03-1983 * Whole abstract *	1-13,22		
A	PEPTIDE CHEMISTRY, vol. 26, 1989, pages 115-118; K. HIGASHIURA et al.: "The general method converting a C-terminal amino acid in peptides into a taurine derivative" * Whole document *	1,3-5, 10,12		
-/-				
The present search report has been drawn up for all claims				
Place of search THE HAGUE		Date of completion of the search 03-07-1992	Examiner GAC G.	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		

EPO FORM 150 (03.92) (P0401)



European Patent  
Office

## EUROPEAN SEARCH REPORT

EP 91 81 0580

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	YAKUGAKU ZASSHI, vol. 107, no. 11, November 1987, pages 917-919; M. SATAKE et al.: "Studies on pharmacological activities of D-cysteinoic acid" * English abstract *	1,2,7,8,10	
X	COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY, vol. 56, no. 1C, 1977, pages 63-37; H. TAKEUCHI et al.: "Structure-activity relationships of GABA and its relatives on the excitability of an identified molluscan giant neurone (Achatina fulica férussac)" * Whole document *	12,14,15,17	
X	PATENT ABSTRACTS OF JAPAN, vol. 12, no. 501 (C-556), 27th December 1988; & JP-A-63 211 263 (NIPPON ZOKI PHARMACEUT. CO., LTD) 02-09-1988 * Whole abstract *	14,19,20	
X	PATENT ABSTRACTS OF JAPAN, vol. 14, no. 322 (C-0739), 10th July 1990; & JP-A-2 115 147 (NIPPON ZOKI PHARMACEUT. CO., LTD) 27-04-1990 * Whole abstract *	14,17,20	
E	WPIL, accession no. 92-030642 [04], Derwent Publications Ltd, London, GB; & JP-A-3 279 355 (NIPPON ZOKI PHARM K.K.) 10-12-1991 * Whole abstract *	14,18,20	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 03-07-1992	Examiner GAC G.
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.92) (P0001)